OA
Orbital ATK, Inc.
Set alert
52-week range unavailable
- YTD
- -100.00%
- 1 year
- -100.00%
- Open
- 134.49
- Prev close
- 134.50
- Mkt cap
- 0
- Vol
- 1.37M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 134.47
- High
- 134.51
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 3, 2018
- 50-d avg
- 0.00
- 200-d avg
- 0.00
News
1 month ago gurufocus.com
Omnicom Advertising Announces Leadership Transition
Omnicom Advertising Announces Leadership Transition PR Newswire NEW YORK, Sept. 9, 2026
4 months ago gurufocus.com
The Hackett Group® Announces Winners of the 2026 Hackett Innovation Awards
[url="]The Hackett Group, Inc. (NASDAQ: HCKT)[/url], an ROI-led AI transformation firm, today announced the winners of its annual [url="]Hackett Innovation Awa
10 months ago gurufocus.com
Eli Lilly's Retatrutide Shows Promising Results in Obesity and Osteoarthritis Trial
Eli Lilly (LLY) is seeing a positive market response after announcing successful topline results from its Phase 3 TRIUMPH-4 clinical trial. The trial evaluated
11 months ago businesswire.com
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the…
1 year ago businesswire.com
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Lenivia approval by Health Canada marks major milestone in the company's continued innovation for canine OA pain.
1 year ago businesswire.com
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.
3 years ago businesswire.com
Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain…
8 years ago businesswire.com
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
NEW YORK, & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc.(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating…
9 years ago businesswire.com
Orbital ATK to Announce Second Quarter 2017 Financial Results on August 3
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its second quarter 2017 financial results prior…
9 years ago businesswire.com
Orbital ATK to Announce First Quarter 2017 Financial Results on May 11
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its first quarter 2017 financial results prior…
9 years ago businesswire.com
Orbital ATK to Announce Fourth Quarter and Full Year 2016 Financial Results on March 8
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its fourth quarter and full year 2016 financial…
9 years ago businesswire.com
Orbital ATK to Conduct Conference Call with Financial Analysts on November 8
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, announced today that it will conduct a conference call with financial analysts to…
10 years ago businesswire.com
Orbital ATK Announces Preliminary Second Quarter 2016 Financial Results
DULLES, VA.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced preliminary unaudited financial results for the second quarter ended…
10 years ago businesswire.com
Orbital ATK Announces First Quarter 2016 Financial Results
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced financial results for the first calendar quarter ended April 3, 2016.…
10 years ago businesswire.com
Orbital ATK to Announce Fourth Quarter and Full Calendar Year 2015 Financial Results on February 29
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will release its financial results for the fourth quarter…
11 years ago businesswire.com
Orbital ATK Announces Third Calendar Quarter 2015 Financial Results
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced both GAAP and adjusted financial results for the third calendar…
11 years ago businesswire.com
Orbital ATK Announces Second Calendar Quarter 2015 Financial Results
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE:OA), a global leader in aerospace and defense technologies, today announced both GAAP and adjusted financial results for the second calendar…
11 years ago businesswire.com
CORRECTING and REPLACING Orbital ATK Announces Financial Results for Quarter Ended March 31, 2015
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK will pay its quarterly dividend for shareholders of record as of June 8 on June 25, not June 28 stated in today’s press release. The correction has been made…
11 years ago businesswire.com
Orbital ATK to Hold Conference Call with Investors and Analysts on February 19
DULLES, Va.--(BUSINESS WIRE)--Orbital ATK, Inc. (NYSE: OA), a global leader in aerospace and defense technologies, today announced that it will hold a conference call with investors and analysts on…